This message is sent to you by FDA Newswatch

Financial & Legal Considerations for Life Sciences Partnerships

December 10-11 2019, Philadelphia, PA

Sponsored by Dynamic Global Events

Click Here to register $1896.00
(Group rate: Register two and third registrant is complimentary)

Click Here to download agenda

Creating innovative life sciences, pharma and biotech mergers and partnership opportunities has never been more critical to organizational growth.  As product offerings grow, the industry is being impacted by rapidly changing market conditions, pricing considerations, and legislative updates. Don’t miss the opportunity to learn from and network with leaders in pharma, life sciences, and M&A.

Through a comprehensive agenda comprised of case studies and expert panels, you’ll gain timely insights into antitrust trends, what CFIUS (the Committee on Foreign Investment in the United States) could mean for your cross-border endeavors, due diligence best practices, and the mechanics of raising series funding. Meet and network with essential industry stakeholders in a collaborative setting.


Tuesday, December 10th, 2019 | Day 1

9:00 AM - 9:15 AM

Chairperson’s Day 1 Opening Remarks

9:15 AM - 12:30 PM

Part 1: Planning & Raising Series Funding & Legal Implications

Start-ups or budding enterprises -- series funding is on your radar. Many NextGen therapeutic developers are finding great success in raising millions to make their respective marks. Laying the foundation for achieving financing is a difficult task but calculated-fundraising efforts are critical.

Participants in this session will:

  • Discover funding sources
  • Learn best practices for successful fundraising
  • Establish actionable plans to achieve funding goals

Ivan Kugener, MD MBA MSc - Vice President, Head of Global Portfolio Management - Global Strategic Excellence
EMD Serono

12:30 PM - 1:30 PM

Networking Lunch

1:30 PM - 3:45 PM

Part 2: Managing Pipeline Opportunity & Risk in a Mid-Size Pharmaceutical Company

Learn how sharing risk and financial burdens with external partners strengthens your partnerships.

This session will:

  • Teach important financial and legal strategies from five recent diverse transactions
  • Uncover how to share financial risks and burdens with external partners
  • Discuss the financial and legal strengths and challenges encountered in several recent partnerships
  • Share techniques to strengthen financial transactions

Ivan Kugener, MD MBA MSc - Vice President, Head of Global Portfolio Management - Global Strategic Excellence
EMD Serono

3:45 PM - 4:15 PM

Chairperson’s Day 1 Closing Remarks

Wednesday, December 11th, 2019 | Day 2

8:00 AM - 9:00 AM

Networking Breakfast

9:00 AM - 9:30 AM

Chairperson’s Day 1 Recap and Day 2 Introduction

9:30 AM - 10:15 AM

KEYNOTE ADDRESS: Strategic Exits - Start from the Beginning!

Although growth drivers in M&A transactions are well understood, the causes of unsuccessful outcomes are seldom discussed.

This session will highlight:

  • Key tools to continuously improve the value of a business
  • Steps business owners can take to increase their purchase price
  • Exit strategy options at various company life stages
  • Pitfalls companies need to avoid for successful strategic exits

David Sheppard - Managing Director

Florence Joffroy-Black – CEO

10:15 AM - 10:30 AM

Morning Networking & Refreshment Break

10:30 AM - 11:15 AM

CASE STUDY: Acquirers Share Their M&A Experiences

M&A veterans will share their insights into financial and legal trends, market drivers and criteria for acquisition opportunities.

Among the questions they will answer are:

  • When is the right time to strike a deal?
  • Sell or acquire – which road to take?
  • How do buyers define value?
  • What criteria and market drivers indicate a good opportunity?

Michael Hong - Chief Investment Officer and Portfolio Manager

Jason Colgate - Managing Director of Private Equity Acquisitions

11:15 AM - 12:00 PM

CASE STUDY: How Smaller Drug Companies Bring New Innovations from Trial to Market

This presentation will disrupt how you think about bringing new drugs to market.

Attendees will:

  • Learn how to pull, instead of push, your drug to market
  • Discuss insights into international options to enhance an organization, making it more attractive for mergers or partnerships
  • Examine steps involved in navigating regulatory bodies on a global level
  • Share criteria used to determine whether a company is a good financial partner

Bill Abajian - Chief Executive Officer, Restructuring, and Turn-Arounds
Eastgate Biotech

12:00 PM - 1:00 PM

Networking Lunch

1:00 PM - 1:45 PM

Intellectual Property Strategies that Close Transactions - Navigating the Legal Process & Attracting Capital

Life science companies can use intellectual property (IP) to make their businesses attractive for strategic partners or buyers.

In this program, participants will:

  • Explore basic questions related to IP development
  • Identify the questions life science companies must answer to attract capital
  • Share techniques companies can use to streamline the due diligence. process
  • Provide legal and financial insights into how to protect revenue streams

Gregory Grissett - Intellectual Property Lawyer and Chair Intellectual Property Group

1:45 PM - 2:30 PM

Mitigating Risk with Due Diligence Best Practices

Due diligence can make or break any deal.

This presentation will cover:

  • Importance of transparency
  • Best practices
  • Opportunities to seize the moment
  • Strategies to mitigate challenges and risks

Rahul Khara - Senior Director, Compliance and Commercial Counsel

2:30 PM - 3:00 PM

Afternoon Networking & Refreshment Break

3:00 PM - 3:45 PM

CASE STUDIES: IPO, Venture Capital, & Legal Alternatives for Product, Portfolio & Market Development

Attend this session to gain a greater understanding of the financing options available to sellers and buyers.

These case studies will:

  • Explore the effects of financial alternatives on transaction types
  • Explain how pharma and biotech companies have executed strategies for successful market share development
  • Uncover techniques to boost therapeutic share development
  • Look at transactions from both the buy and sell side

Bill Abajian - Chief Executive Officer, Restructuring, and Turn-Arounds

Michael Hong - Chief Investment Officer and Portfolio Manager

Jason Colgate - Managing Director of Private Equity Acquisitions

3:45 PM - 4:15 PM

Open Forum Q&A